Skip to main content

Market Overview

Why ChromaDex Shares Spiked 111% Today

Why ChromaDex Shares Spiked 111% Today

Chromadex Corp (NASDAQ: CDXC) shares jumped 111% in the regular and after-hours sessions today.

What Happened: The price movement on Thursday was accompanied by intense trading with volumes of 116.67 million. The average volume for ChromaDex shares is 523,511.

While there were no immediate triggers for share movement on Thursday, the bioscience company announced results from a Phase 3 study that examined its nutritional protocol in the treatment of COVID-19, a day prior. 

See also: Best Healthcare Penny Stocks

“The nutritional protocol significantly improves the recovery, liver health, and markers of inflammation of patients with COVID-19,” said Adil Mardinoglu, a professor at King’s College London, as per a company statement. 

“Dysfunctional mitochondria have been implicated in worsened progression for COVID-19, and this nutritional intervention helps to remedy the stress put on the body of an infected patient,” said the professor. 

On Monday, ChromaDex said it had entered into a securities purchase agreement for the sale of $25 million of its common stock in a private placement.

The company agreed to sell nearly 3.84 million of its common stock at a per-share price of $6.50, according to a separate statement.

Price Action: ChromaDex shares closed 92.4% higher at $18.74 on Thursday and spiked another 18.38% in the after-hours to $22.24.


Related Articles (CDXC)

View Comments and Join the Discussion!

Posted-In: clinical trials Covid-19Biotech News Small Cap Movers Trading Ideas General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at